Is Extracellular Volume Expansion of Peritoneal Dialysis Patients Associated with Greater Urine Output?

2011 ◽  
Vol 32 (3) ◽  
pp. 226-231 ◽  
Author(s):  
Andrew Davenport ◽  
Rabya Hussain Sayed ◽  
Stanley Fan
Keyword(s):  
Peritoneal Dialysis ◽  
Urine Output ◽  
Volume Expansion ◽  
Extracellular Volume ◽  
Dialysis Patients ◽  
Extracellular Volume Expansion

Extracellular Volume Expansion Caused by Protein Malnutrition in Peritoneal Dialysis Patients with Appropriate Salt and Water Removal

2008 ◽  
Vol 28 (4) ◽  
pp. 407-412 ◽  
Author(s):  
M.-José Fernández-Reyes ◽  
M.-Auxiliadora Bajo ◽  
Gloria del Peso ◽  
Dabaiba Regidor ◽  
Covadonga Hevia ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Volume Expansion ◽  
Extracellular Volume ◽  
Protein Malnutrition ◽  
Water Removal ◽  
Dialysis Patients ◽  
Extracellular Volume Expansion

Role of Oxytocin in the Natriuresis of Extracellular Volume Expansion

1969 ◽  
Vol 130 (4) ◽  
pp. 1276-1279 ◽  
Author(s):  
S. G. Massry ◽  
H. Vorherr ◽  
C. R. Kleeman
Keyword(s):  
Volume Expansion ◽  
Extracellular Volume ◽  
Extracellular Volume Expansion

scholarly journals Systemic Endotoxin in Peritoneal Dialysis Patients

2018 ◽  
Vol 38 (5) ◽  
pp. 381-384 ◽  
Author(s):  
Ali M. Shendi ◽  
Nathan Davies ◽  
Andrew Davenport
Keyword(s):  
Peritoneal Dialysis ◽  
Extracellular Volume ◽  
Peritoneal Membrane ◽  
Dialysis Patients ◽  
Fungal Cell ◽  
Membrane Function ◽  
Patient Demographics ◽  
Markers Of Inflammation ◽  
Systemic Endotoxemia

Previous reports linked systemic endotoxemia in dialysis patients to increased markers of inflammation, cardiovascular disease, and mortality. Many peritoneal dialysis (PD) patients use acidic, hypertonic dialysates, which could potentially increase gut permeability, resulting in systemic endotoxemia. However, the results from studies measuring endotoxin in PD patients are discordant. We therefore measured systemic endotoxin in 55 PD outpatients attending for routine assessment of peritoneal membrane function; mean age 58.7 ± 16.4 years, 32 (58.2%) male, 21 (38.2%) diabetic, median duration of PD treatment 19.5 (13 – 31) months, 32 (58.2%) using 22.7 g/L dextrose dialysates, and 47 (85.5%) icodextrin. The median systemic endotoxin concentration was 0.0485 (0.0043 – 0.103) Eu/mL. We found no association between endotoxin levels and patient demographics, markers of inflammation, serum albumin, N-terminal pro-brain natriuretic peptide, extracellular volume measured by bioimpedance, blood pressure, PD prescriptions or peritoneal membrane transporter status, or medications. The measurement of endotoxin can be lowered by failure to effectively release protein-bound endotoxin prior to analysis and increased by contamination when taking blood samples and processing and storing the samples. Additionally, contamination with β–glucan from fungal cell walls and the use of different assays to analyze endotoxin can also give differing results. These factors may help to explain the disparate results reported in different studies. Our study would suggest that exposure to standard peritoneal dialysates does not substantially increase systemic endotoxin. However, until endotoxin assays can measure free and bound endotoxin separately, the role of endotoxin causing inflammation in PD patients remains to be determined.

Sign in / Sign up

Export Citation Format

Share Document